Summary
Drug-induced myelotoxicity is usually the dose-limiting factor of treatment of malignant tumors with cytostatic drugs. Suppression of in vitro myelopoiesis (CFU-GM) by cytostatics may be a suitable model reflecting the in vivo situation. Thus the inhibitory effects of the anthracyclines doxorubicin, theprubicin, idarubicin and cytorhodin S on CFU-GM were compared. Normal human bone marrow cells were incubated with these drugs for one hour and alternatively, for the whole culture period. For each substance and each incubation time a dose-response curve was established and the D50 determined. As certain calcium antagonists can increase the toxicity of some cytostatic drugs in various tumor models, the effect of the addition of verapamil (2µM) was also investigated. It could be shown, that the myelotoxicity on CFU-GM of the drugs mentioned above was not increased after short-term or permanent exposure to this calcium antagonist.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096–6101
Busch FW, deVos S, Flehmig B, Herrmann F, Sandler Ch, Vallbracht A (1987) Inhibition of in vitro hematopoiesis by hepatitis A virus. Exp Hematol 15: 978–982
Durie BGM, Dalton WS (1988) Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 68: 203–206
Fine RL, Koizumi S, Curt GA, Chabner BA (1987) Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol 5: 489–495
Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417–3421
Hill BT, Dennis LY, Li XT, Whelan RDH (1985) Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 14: 194–201
Krishan A, Sauerteig A, Gordon K, Swinkin C (1986) Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells. Cancer Res 46: 1768–1773
Mergenthaler H-G, Brühl P, Ehninger G, Heidemann E (1987) Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Cancer Chemother Pharmacol 20: 8–12
Miller AA, Schmidt CG (1987) Clinical pharmacology and toxicity of 4′-0-tetrahydropyranyladriamycin. Cancer Res 47: 1461–1465
Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641–647
Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF (1984) Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994–996
Sahar E, Michalevicz R, Broudo I, Seligsohn U (1986) Quantitation by flow cytometry of anthracycline drug uptake by peripheral blood and bone marrow cells in human leukemias. Exp Hematol 14: 119–125
Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ (1986) 9-Alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Br J Cancer 53: 595–600
Smith MA, Merry S, Smith JG, Kaye SB (1988) Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP-16. Br J Cancer 57: 576–578
Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y (1982) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P 388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31: 3138–3140
Yalowich JC, Zucali JR, Gross MA, Ross WE (1985) Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K 562 leukemia cells in vitro. Cancer Res 45: 4921–4924
Author information
Authors and Affiliations
Additional information
This work was supported by Deutsche Forschungsgemeinschaft (SFB 120/C 2)
Rights and permissions
About this article
Cite this article
Busch, F.W., Schmittele, U. & Ehninger, G. Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil. Blut 60, 219–222 (1990). https://doi.org/10.1007/BF01728787
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728787